Summary:
In adults with long-standing T2D inadequately controlled on current therapy, subcutaneous tirzepatide (dual GIP/GLP-1 agonist) in Phase 1 trial significantly enhanced both first- and second-phase insulin secretion, improved whole-body insulin sensitivity, and enabled normoglycemia achievement compared to semaglutide (selective GLP-1 RA) and placebo, demonstrating mechanistic superiority of dual agonism over selective GLP-1 agonism.
| PICO | Description |
|---|---|
| Population | Adults with long-standing T2D inadequately controlled on current therapy. |
| Intervention | Tirzepatide (dual GIP/GLP-1 agonist), Phase 1 randomized double-blind trial. |
| Comparison | Semaglutide (selective GLP-1 RA) and placebo with metabolic phenotyping. |
| Outcome | Enhanced beta-cell function and insulin sensitivity. Normoglycemia achieved in established T2D. |
Clinical Context
Tirzepatide combines GIP and GLP-1 receptor agonism. GIP acts on beta-cells and adipose tissue; GLP-1 affects beta-cells, appetite, and gastric emptying.
Clinical Pearls
1. Dual Agonism Provides Mechanistic Superiority: Enhanced both beta-cell function AND insulin sensitivity beyond semaglutide.
2. First-Phase Insulin Secretion Improved: Suggests meaningful beta-cell functional recovery.
3. Normoglycemia Achieved in Established T2D: Approaches diabetes remission in some patients.
4. GIP Receptor Agonism Contributes Meaningfully: Superiority over semaglutide validates dual approach.
Practical Application
Consider tirzepatide for significant beta-cell dysfunction or prominent insulin resistance. Switching from GLP-1 RA leverages distinct mechanism.
Study Limitations
Phase 1 small selected population. Intensive assessments not feasible routinely. Long-term durability unknown.
Bottom Line
Tirzepatide’s dual GIP/GLP-1 agonism produces mechanistically superior improvements in beta-cell function and insulin sensitivity, enabling normoglycemia.
Source: Heise T, et al. “Effects of tirzepatide on pancreatic islet function and insulin sensitivity in T2D.” Lancet Diabetes Endocrinol. Read article
